Faricimab gave similar gains to aflibercept in Indian diabetic macular oedema, with longer gaps between injections

The edition in brief

A single-centre randomised trial in India assigned 74 treatment-naive patients with diabetic macular oedema to faricimab 6 mg or aflibercept 2 mg, with three loading doses then as-needed retreatment. At 48 weeks, visual acuity gains (about −0.37 logMAR) and central thickness reductions were similar, while faricimab achieved longer mean intervals between injections (12.9 vs 9.5 weeks). For Indian patients, for whom each visit and injection carries cost and travel, fewer injections may matter as much as vision gains, though the trial is small. A network meta-analysis of seven studies (992 participants) found adalimumab the best-supported systemic therapy for non-infectious uveitis, reducing treatment failure versus placebo (RR 0.67), with more injection-site reactions; comparative safety of other agents remains uncertain. A meta-analysis of AI on ultrawide-field fundus images for diabetic retinopathy screening found sensitivity of 85.0% but specificity of only 72.5%, from four studies all using one manufacturer's software. An American Academy of Ophthalmology evidence review of 11 studies found mitomycin C by injection or by sponge gave similar trabeculectomy success and safety, with injection possibly producing more favourable blebs. The pearl covers excluding infection before immunosuppression in uveitis.